AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MBRX
  4. [8-K] Moleculin Biotech, Inc. Reports Material Event

[8-K] Moleculin Biotech, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock MBRX logo
Moleculin Biotec

NASDAQ:MBRX

MBRX Rankings

#9135 Ranked by Market Cap
N/A Ranked by Dividends

MBRX Latest News

Jul 30, 2025
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
Jul 22, 2025
Moleculin Participates in the Virtual Investor “What’s Your Story� Summer Spotlight On-Demand Conference
Jul 17, 2025
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Jul 9, 2025
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Jun 20, 2025
Moleculin Announces $5.9 Million Public Offering

MBRX Latest SEC Filings

Jul 30, 2025
[8-K] Moleculin Biotech, Inc. Reports Material Event
Jul 11, 2025
[8-K] Moleculin Biotech, Inc. Reports Material Event
Jul 11, 2025
[424B5] Moleculin Biotech, Inc. Prospectus Supplement (Debt Securities)
Jul 9, 2025
[8-K] Moleculin Biotech, Inc. Reports Material Event
Jul 8, 2025
[DEFA14A] Moleculin Biotech, Inc. Additional Proxy Soliciting Materials

MBRX Stock Data

21.58M
29.14M
0.75%
3.49%
9.01%
Biotechnology
Pharmaceutical Preparations
United States
HOUSTON